Compare Liberty Energy Inc. Class A common stock (LBRT) vs Tango Therapeutics Inc. (TNGX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Liberty Energy Inc. Class A common stock vs Tango Therapeutics Inc. — how do they compare? Liberty Energy Inc. Class A common stock trades at $17.99 (market cap $3.12B), while Tango Therapeutics Inc. trades at $22.23 (market cap $3.75B). The key difference: Tango Therapeutics Inc. is the larger of the two by market cap, and Liberty Energy Inc. Class A common stock pays a 1.88% dividend while Tango Therapeutics Inc. pays none. Which is the better fit depends on your goals — on Pluang, investors hold Liberty Energy Inc. Class A common stock for 6 Days and Tango Therapeutics Inc. for 0 Days on average.
| LBRT | TNGX | |
|---|---|---|
Market Cap | $3.12B | $3.75B |
Volume | 2,205,743 | 9,619,106 |
Sector | Energy | Health |
52-Week High | $33.93 | $32.90 |
52-Week Low | $11.94 | $7.50 |
Typical Hold Time | 6 Days | 0 Days |
Enterprise Value | $4.18B | $2.77B |
Dividend Yield | 1.88% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Liberty Energy (LBRT) trades at $19.11, up 0.68% today, with a bearish technical signal but strong analyst support. The stock has beaten earnings estimates for three consecutive quarters, with Q3 2026 results expected soon. Revenue reached $4.01B in 2025, though net margins are thin at 2.92%. Valuation metrics like P/E of 25.82 and P/S of 0.75 suggest mixed attractiveness relative to profitability.
Outlook is cautiously optimistic given earnings momentum and a $28.38 consensus price target, but risks include margin pressure from rising costs and execution challenges in expanding into data center power. The stock's proximity to its 52-week low of $19.00 highlights downside vulnerability if Q3 results disappoint.
TNGX trades at $22.22, down 8.07% in the last session, reflecting negative investor reaction to recent earnings misses. The stock shows neutral technical signals with key support at $21 and resistance at $23. Fundamentally, the company maintains a high gross margin of 98.25% but faces significant losses with a net income margin of -229.92% and negative cash flow from operations. Recent news highlights institutional buying interest and upcoming clinical trial developments.
Despite strong analyst support with a $45.91 consensus price target (107% upside), TNGX faces substantial execution risks as a clinical-stage biotech. The company's heavy cash burn and lack of profitability require careful monitoring of pipeline progress. Investment appeal hinges on successful drug development outcomes rather than current financial metrics.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About Liberty Energy Inc. Class A common stock
Liberty Energy provides completion services and technologies for onshore oil, natural gas, and geothermal producers in North America. It also offers distributed power and energy-storage solutions through Liberty Power Innovations.
Read more on LBRT →About Tango Therapeutics Inc.
Tango Therapeutics, Inc. is a clinical-stage biotechnology company focused on precision oncology, developing cancer therapies based on the genetic principle of synthetic lethality, including its PRMT5 inhibitor program.
Read more on TNGX →
